Description

Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments. Central to their efforts is the proprietary, genome-wide, and CRISPR-enabled SNIPRx platform, which systematically uncovers and advances highly targeted cancer medicines. These therapies are specifically designed to address genomic instability, particularly related to DNA damage repair mechanisms. Their primary investigational drug is RP-3500, an oral small molecule inhibitor currently being developed to treat solid tumors that possess specific genomic alterations linked to DNA damage repair. Repare is also advancing RP-6306, which is in Phase I clinical trials for tumors characterized by genetic alterations involving CCNE1 amplification. Furthermore, the company is pursuing a Polymerase Theta program, investigating a synthetic lethal target relevant to BRCA mutations and other genomic abnormalities. Repare Therapeutics Inc. was established in 2016 and maintains its headquarters in Montreal, Canada.